Biocon Ltd (BIOCON)

Biocon Stock Attracts Interest from Mugul and Calculator PMS - 30 Apr, 2024

There are reports of significant buying activity in Biocon stock by Mugul, with rumors of a potential change in senior leadership. Additionally, the Calculator PMS has also shown interest in the long-term prospects of the company.

Biocon Shows Signs of Momentum - 29 Apr, 2024

Experts suggest that Biocon Ltd is showing signs of momentum and short-term traders can look to buy the stock now for a possible target of 325-350 levels in the next 3-4 weeks.

Biocon Pharma Receives Approval for Amalgamation; Biocon Ltd Gains for Fifth Straight Session - 26 Apr, 2024

Biocon Pharma has received approval from the National Company Law Tribunal (NCLT) to amalgamate Biofusion Therapeutics with itself. Meanwhile, Biocon Ltd's stock has gained for the fifth consecutive session and is up by 18.22% in the last one month.

Biocon and Syngene International See Positive Developments - 25 Apr, 2024

Biocon sees a rise in total income and net profit after tax for Q3 FY24, while Anand Rathi issues a buy call with a target price of Rs 340. Meanwhile, Syngene International announces a significant increase in dividends as global pharma companies seek alternatives to China.

Biocon Shares Rise on Weight-Loss Drug Development News - 24 Apr, 2024

Biocon Ltd's stock rose by over 4% after reports emerged that it was developing its own weight-loss drug. The company has seen significant gains in the past year and currently has a PE ratio of 0 based on TTM earnings.

Biocon Receives Approval for Tacrolimus Capsule in South Africa - 22 Apr, 2024

Biocon has received approval from the South African Health Products Regulatory Authority for their drug product Tacrolimus capsule used in organ transplant patients. Additionally, Biocon reported a consolidated net profit of Rs 660 crore in Q3 FY24 with a YoY revenue jump of 34.43%.

Biocon Receives Approval for Tacrolimus Capsule in South Africa - 20 Apr, 2024

Biocon has received approval from the South African Health Products Regulatory Authority (SAHPRA) for their drug product Tacrolimus capsule, used to treat organ transplant patients. The company reported a consolidated net profit of Rs 660 crore in Q3 FY24 and revenue from operations jumped 34.43% YoY to Rs 3,953.7 crore. However, the stock fell by 2.10% on Friday, April 19, 2024.

Biocon Signs Licensing Agreement with Biomm for Commercialisation of Semaglutide in Brazil - 18 Apr, 2024

Biocon has signed a licensing and supply agreement with Biomm SA for the commercialisation of its diabetes drug Semaglutide (gOzempic) in Brazil. Biocon will undertake development, manufacturing and supply of the drug product, while Biomm will be responsible for obtaining regulatory approval and commercialisation in the Brazilian market. The potential market for Semaglutide in Brazil stands at around $580 million.

Biocon Partners with Biomm SA for Diabetes Drug Commercialisation in Brazil - 17 Apr, 2024

Biocon has partnered with Biomm SA for the commercialisation of its diabetes drug Semaglutide (gOzempic) in Brazil. Meanwhile, ICICI Securities expects Biocon's Q4 net profit to be at Rs 67.1 crore, down 192.8% YoY.

Biocon Pivots to Anti-Obesity Therapies Amid Patent Expirations - 08 Apr, 2024

Biocon Ltd is leading Indian drugmakers in the race to grab a slice of the $100 billion obesity drugs market, as patents for blockbuster medications start to expire. Biocon has scored an early win among its peers with UK approval for the first generic version of liraglutide injectable.

Biocon Transfers Branded Formulations Business to Eris Lifesciences - 03 Apr, 2024

Biocon Biologics has completed the transfer of its branded formulations business in India to Eris Lifesciences for Rs 1,242 crore. The transaction was conducted on a slump sale basis and includes metabolics, oncology, and critical care diagnostics.

Biocon Receives Approval for gSaxenda Formulation - 01 Apr, 2024

Biocon's complex formulation Liraglutide (gSaxenda) has received approval from MHRA, UK, leading to a 1.7% rise in the company's stock. The pharmaceuticals and drugs sector saw investments exceeding expectations, with Biocon being one of the major beneficiaries. In Q3 FY24, Biocon reported a consolidated net profit of Rs 660 crore.